Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

TISSUE REGENERATION

Anti-aging therapy for pulmonary fibrosis

Nature Aging volume 1, pages 155–156 (2021)Cite this article

Subjects

Accelerated aging and cellular senescence are driving forces of pulmonary fibrosis. A novel anti-aging therapeutic approach combats lung fibrosis by targeting senescent fibrogenic cells for apoptosis.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Anti-aging therapy for pulmonary fibrosis.

References

  1. Patterson, K. C. et al. Chest 151, 838–844 (2017).

    Article  Google Scholar 

  2. Gulati, S. & Thannickal, V. J. Am. J. Med. Sci. 357, 384–389 (2019).

    Article  Google Scholar 

  3. Merkt, W., Bueno, M., Mora, L. A. & Lagares, D. Semin. Cell Dev. Biol. 101, 104–110 (2020).

    Article  CAS  Google Scholar 

  4. Rehan, M. et al. Nat. Aging https://doi.org/10.1038/s43587-021-00027-5 (2021).

  5. Martinez, F. J. et al. Nat. Rev. Dis. Primers 3, 17074 (2017).

    Article  Google Scholar 

  6. Hinz, B. & Lagares, D. Nat. Rev. Rheumatol. 16, 11–31 (2020).

    Article  CAS  Google Scholar 

  7. Armanios, M. Y. et al. New Engl. J. Med. 356, 1317–1326 (2007).

    Article  CAS  Google Scholar 

  8. Alder, J. K. et al. Proc. Natl Acad. Sci. USA 112, 5099–5104 (2015).

    Article  CAS  Google Scholar 

  9. Rose, G. et al. Exp. Gerontol. 38, 1065–1070 (2003).

    Article  CAS  Google Scholar 

  10. North, B. J. & Verdin, E. Genome Biol. 5, 224 (2004).

    Article  Google Scholar 

  11. Haigis, M. C. & Guarente, L. P. Genes Dev. 20, 2913–2921 (2006).

    Article  CAS  Google Scholar 

  12. Tseng, A. H., Shieh, S.-S. & Wang, D. L. Free Radic. Biol. Med. 63, 222–234 (2013).

    Article  CAS  Google Scholar 

  13. Ferber, E. C. et al. Cell Death Differ. 19, 968–979 (2012).

    Article  CAS  Google Scholar 

  14. Lagares, D. et al. Sci. Transl. Med. 9, eaal3765 (2017).

    Article  Google Scholar 

  15. Hecker, L. et al. Sci. Transl. Med. 6, 231ra247 (2014).

    Article  Google Scholar 

Download references

Acknowledgements

D.L. gratefully acknowledges funding support from the NIH (grant R01 HL147059-01), the start-up package from Massachusetts General Hospital and sponsored research grants from Boehringer Ingelheim.

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

    Yan Zhou & David Lagares

  2. Fibrosis Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

    Yan Zhou & David Lagares

  3. Center for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, USA

    Yan Zhou & David Lagares

  4. Department of Physiology, Xiangya Medical School, Central South University, Hunan, China

    Yan Zhou

Authors
  1. Yan Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David Lagares
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David Lagares.

Ethics declarations

Competing interests

D.L. declares that he has received research funding from Boehringer Ingelheim, Indalo Therapeutics, Merck and Unity Biotechnology. D.L. has a financial interest in Mediar Therapeutics and Zenon Biotech. The companies are developing treatments for organ fibrosis. D.L.’s interests were reviewed and are managed by MGH and Partners HealthCare in accordance with their conflict of interest policies.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhou, Y., Lagares, D. Anti-aging therapy for pulmonary fibrosis. Nat Aging 1, 155–156 (2021). https://doi.org/10.1038/s43587-021-00035-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s43587-021-00035-5

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing